OTCMKTS:CAPSCapstone Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Capstone Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.00 +2.00 (+12.50 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$18.00Now: $18.00▼$18.0050-Day Range$16.00MA: $16.16▼$18.0052-Week Range$12.00Now: $18.00▼$26.00Volume130 shsAverage Volume237 shsMarket Capitalization$972,000.00P/E RatioN/ADividend YieldN/ABeta239.63 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Capstone Therapeutics. Previous Next 3.0 Community Rank Outperform VotesCapstone Therapeutics has received 60 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCapstone Therapeutics has received 39 “underperform” votes. (Add your “underperform” vote.)Community SentimentCapstone Therapeutics has received 60.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote “Outperform” if you believe CAPS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CAPS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCapstone Therapeutics does not currently pay a dividend.Dividend GrowthCapstone Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Capstone Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.80% of the stock of Capstone Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.80 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CAPS Previous Symbol CUSIPN/A CIK887151 Webwww.capstonethx.com Phone602-286-5520Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value($22.87) per share Price / Book-0.79Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares54,000Market Cap$972,000.00 Next Earnings Date6/1/2020 (Estimated) OptionableNot Optionable OTC:CAPS Rates by TradingView Receive CAPS News and Ratings via Email Sign-up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions How has Capstone Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Capstone Therapeutics' stock was trading at $16.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CAPS shares have increased by 10.8% and is now trading at $18.00. View which stocks have been most impacted by Coronavirus. When is Capstone Therapeutics' next earnings date? Capstone Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for Capstone Therapeutics. How were Capstone Therapeutics' earnings last quarter? Capstone Therapeutics Corp (OTCMKTS:CAPS) released its quarterly earnings data on Monday, August, 13th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2 million for the quarter. View Capstone Therapeutics' earnings history. Has Capstone Therapeutics been receiving favorable news coverage? Press coverage about CAPS stock has trended negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Capstone Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutCapstone Therapeutics. Who are some of Capstone Therapeutics' key competitors? Some companies that are related to Capstone Therapeutics include IntelliPharmaCeutics Intl (IPCIF), Parnell Pharmaceuticals (PARNF), Wellness Center USA (WCUI), Wize Pharma (WIZP), Innovus Pharmaceuticals (INNVD), Global Future City (FTCY), Boston Therapeutics (BTHE), Praxsyn (PXYN), THERAPIX BIOSCI/S (TRPX), Earth Science Tech (ETST), Peak Pharmaceuticals (PKPH), Achaogen (AKAOQ), Anthera Pharmaceuticals (ANTH), Argos Therapeutics (ARGSQ) and Sienna Biopharmaceuticals (SNNAQ). View all competitors. What other stocks do shareholders of Capstone Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capstone Therapeutics investors own include Energy Transfer LP Unit (ET), Energy Transfer Equity LP Unit (ETE), Checkpoint Systems (CKP), BioLife Solutions (BLFS), Ballard Power Systems (BLDP), Booking (BKNG), Alibaba Group (BABA), Activision Blizzard (ATVI), Atlantic Power (AT) and Amira Nature Foods (ANFI). Who are Capstone Therapeutics' key executives? Capstone Therapeutics' management team includes the following people: Mr. John M. Holliman III, Exec. Chairman & Principal Exec. Officer (Age 65)Mr. Leslie M. Taeger, Sr. VP, CFO and Principal Accounting & Financial Officer (Age 68)Dr. Randolph C. Steer, Consultant (Age 69)Dr. William M. Wardell M.D., Ph.D., Head of Clinical & Regulatory Review Board (Age 80)Ms. Karen Struck, Investor Relations Professional What is Capstone Therapeutics' stock symbol? Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS." How do I buy shares of Capstone Therapeutics? Shares of CAPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Capstone Therapeutics' stock price today? One share of CAPS stock can currently be purchased for approximately $18.00. How big of a company is Capstone Therapeutics? Capstone Therapeutics has a market capitalization of $972,000.00 and generates $2 million in revenue each year. What is Capstone Therapeutics' official website? The official website for Capstone Therapeutics is www.capstonethx.com. How can I contact Capstone Therapeutics? Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
